TICO-STEMI: In STEMI, Ticagrelor Alone Reduces Bleeding, Does Not Increase Ischemia vs. DAPT After PCI
In patients with ST-elevation myocardial infarction (STEMI) who underwent percutaneous coronary intervention (PCI) followed by 3 months of dual antiplatelet therapy (DAPT), 9 months of ticagrelor monotherapy reduced major bleeding risk and resulted in comparable ischemic risk as compared to DAPT with ticagrelor and aspirin, according to late-breaking science results presented Wednesday at the TCT Connect virtual conference.